Studies on the frequency of PDL-1 positive peripheral mononuclear cells and blood level of soluble PDL-1 in pancreatic cancer patients treated with dendritic cell therapy

Studies on the frequency of PDL-1 positive peripheral mononuclear cells and blood level of soluble PDL-1 in pancreatic cancer patients treated with dendritic cell therapy - Studies on the frequency of PDL-1 positive peripheral mononuclear cells and blood level of soluble PDL-1 in pancreatic cancer patients treated with dendritic cell therapy

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000029377

Enrollment

Registered

2018-06-30

Start date

2015-06-18

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pancreatic cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Pancreatic cancer patients treated with the dendritic cell therapy in Kashiwa Hospital of Jikei University School of Medicine

Exclusion criteria

Exclusion criteria: Pancreatic cancer patients not applicable to the dendritic cell therapy

Design outcomes

Primary

Measure	Time frame
Frequency of PDL-1 positive peripheral mononuclear cells	—

Secondary

Measure	Time frame
Concentration of blood soluble PDL-1	—

Countries

Japan

Contacts

Public ContactSadamu Homma

Jikei University School of Medicine Division of Oncology

sahya@jikei.ac.jp03-3433-1111

Outcome results